Elaborating the potential of Artficial Intelligence in automated CAR-T cell manufacturing

This paper discusses the challenges of producing CAR-T cells for cancer treatment and potential Artificial Intelligence (AI) its improvement. cell therapy was approved in 2018 as first Advanced Therapy Medicinal Product (ATMP) treating acute leukemia lymphoma. ATMPs are cell- gene-based therapies that show great promise various cancers hereditary diseases. While some new have been approved, ongoing clinical trials expected to lead approval many more. However, production presents a significant challenge due high costs associated with manufacturing process, making very expensive (approx. $400,000). Furthermore, autologous is limited make-to-order approach, which makes scaling economical difficult. First attempts being made automate this multi-step will not only directly reduce but also enable comprehensive data collection. AI technologies ability analyze convert it into knowledge insights. In order exploit these opportunities, analyses automated process creates mapping capabilities applications. The explores possible use analyzing generated during further improve efficiency cost-effectiveness production.